Oral Tolvaptan (Samsca) Is Safe and Effective in Chronic Hyponatremia - medical center information, medical center, health care, disease, medical journal

Vasopressin antagonists increase the serum sodium concentration in patients who have euvolemia and hypervolemia with hyponatremia in the short term (30 days), but their safety and efficacy with longer term administration is unknown.

In a study, 111 patients with hyponatremia received oral tolvaptan (Samsca) for 700 days.

The most common adverse effects attributed to tolvaptan were pollakiuria, thirst, fatigue, dry mouth, polydipsia, and polyuria.

Mean serum sodium increased from 130.8 mmol/L at baseline to greater than 135 mmol/L throughout the observation period.

Responses were comparable between patients with euvolemia and those with heart failure but more modest in patients with cirrhosis.

In conclusion, prolonged administration of tolvaptan maintains an increased serum sodium with an acceptable margin of safety.

Related Posts

• Quintiles to More Heavily Directly Invest in the Drugs Which it Evaluates - But Not to Worry, Says an Expert?
• Toasted at the Lean Conference
• First official antismoking campaign was launched in 1604 by James I of England
• Unneccesary Medical Tests: Tort Reform Can't Solve it All
• Color Atlas of Pathophysiology, 1st ed. 2000
• Video: A life cycle in 90 seconds
• Standardized patient: Over the course of three days, I had 23 head-to-toe physicals from 23 medical students
• Stop Medical Malpractice: The White Coat Wall of Silence
• Pediatric and Adolescent Gynecology, 5th ed. 2005
• I was not skeptical enough
• A Bayesian Brain is a Freudian Brain
• Old drug, new warnings: Acetaminophen (paracetamol, Tylenol)
• EHRevent.org and "The National Database of EHR Errors Being Called For" - Where's the Beef?
• No way to run a hospital
• What Is Multiple Sclerosis?